Matches in Nanopublications for { <http://www.w3.org/1999/02/22-rdf-syntax-ns#SUBJECT> ?p ?o ?g. }
- SUBJECT label "dexamethasone , insulin , transferrin , selenium , putrescine" provenance.
- SUBJECT label "dexamethasone , insulin , transferrin , selenium , putrescine" provenance.
- SUBJECT label "Only dexamethasone" provenance.
- SUBJECT label "Only dexamethasone" provenance.
- SUBJECT label "Only dexamethasone" provenance.
- SUBJECT label "Only dexamethasone" provenance.
- SUBJECT label "Only dexamethasone" provenance.
- SUBJECT label "Only dexamethasone" provenance.
- SUBJECT label "Only dexamethasone" provenance.
- SUBJECT label "Only dexamethasone" provenance.
- SUBJECT label "Only dexamethasone" provenance.
- SUBJECT label "Only dexamethasone" provenance.
- SUBJECT label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater" provenance.
- SUBJECT label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater" provenance.
- SUBJECT label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater" provenance.
- SUBJECT label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater" provenance.
- SUBJECT label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater" provenance.
- SUBJECT label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater" provenance.
- SUBJECT label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater" provenance.
- SUBJECT label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater" provenance.
- SUBJECT label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater" provenance.
- SUBJECT label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater" provenance.
- SUBJECT label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater" provenance.
- SUBJECT label "Consistent detection of PGE2 and 5-iPF2α-VI in wastewater" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "lenalidomide and dexamethasone ( DRd ) significantly prolonged progression-free survival in transplant-ineligible patients with newly diagnosed multiple myeloma" provenance.
- SUBJECT label "treatment of Covid-19 with dexamethasone" provenance.
- SUBJECT label "treatment of Covid-19 with dexamethasone" provenance.
- SUBJECT label "treatment of Covid-19 with dexamethasone" provenance.
- SUBJECT label "treatment of Covid-19 with dexamethasone" provenance.
- SUBJECT label "treatment of Covid-19 with dexamethasone" provenance.
- SUBJECT label "treatment of Covid-19 with dexamethasone" provenance.
- SUBJECT label "treatment of Covid-19 with dexamethasone" provenance.
- SUBJECT label "treatment of Covid-19 with dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "low-dose dexamethasone" provenance.
- SUBJECT label "the corticosteroid dexamethasone" provenance.
- SUBJECT label "the corticosteroid dexamethasone" provenance.
- SUBJECT label "the corticosteroid dexamethasone" provenance.